Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%

Zomedica Corp.

2025-Q2 EPS reported -$0.07 revenue$13,464,000

Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.
Diagnostics segment revenue $0.8M (+86%), driven by TRUFORMA platform adoption.
Net loss $7.4M vs $23.9M (including $16M impairment) in Q2 2024; Adj. EBITDA loss $5.5M.
Operating expenses down $0.7M excluding impairment; liquidity $59.1M.
Record 18th consecutive quarter of YoY revenue growth; consumable sales up 21%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.